What is Mysimba?
Your doctor has prescribed Mysimba to help you achieve the best weight for you. 1
Mysimba is a medicine used along with diet and exercise to help manage weight in adults: 1
- who are obese (have a body-mass index (BMI) of 30 kg/m2 or more);
- who are overweight (have a BMI between 27 kg/m2 and 30 kg/m2 ) and have weight-related complications such as diabetes, abnormally high levels of fat in the blood, or high blood pressure.
(BMI is a measurement that indicates body weight relative to height.)
The two active substances, naltrexone and bupropion, act on the parts of the brain that help to control food intake and energy balance, as well as those that control the pleasure associated with eating food.1*
More information on Mysimba can be found in your Mysimba Package Leaflet
Note: A patient card is included inside each pack of Mysimba. Write your name and your doctor’s name and telephone number on this card. Carry the patient card with you at all times. It is important that you inform healthcare professionals that you are taking Mysimba in case of surgery.
Mode of Action Video
Patient Information Booklet
References
- Click here to view the Mysimba package leaflet.
*Other areas of the brain may be involved. The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood.
IE-MYS-220(1), MMYS-0454-001 01/26 DOP:January 2026
The information on this website is intended for patients who have been prescribed Mysimba who reside in Ireland and Malta only.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Patients who reside in Malta are asked to report any side effects or suspected adverse events to the Malta Medicines Authority via http://medicinesauthority.gov.mt/adrportal or Vivian Corporation Ltd. via pv@viviancorp.com or +356 22588600.
Adverse events should also be reported to Orexigen : +356 800 62176 or Currax.MI@primevigilance.com
Patients who reside in Ireland are asked to report any suspected adverse events to: HPRA Pharmacovigilance via www.hpra.ie;
Adverse events should also be reported to Orexigen: +353 1800 849 099 or Currax.Ml@primevigilance.com.